A citation-based method for searching scientific literature

Karim Fizazi, Howard I Scher, Arturo Molina, Christopher J Logothetis, Kim N Chi, Robert J Jones, John N Staffurth, Scott North, Nicholas J Vogelzang, Fred Saad, Paul Mainwaring, Stephen Harland, Oscar B Goodman, Cora N Sternberg, Jin Hui Li, Thian Kheoh, Christopher M Haqq, Johann S de Bono. Lancet Oncol 2012
Times Cited: 905







List of co-cited articles
591 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Increased survival with enzalutamide in prostate cancer after chemotherapy.
Howard I Scher, Karim Fizazi, Fred Saad, Mary-Ellen Taplin, Cora N Sternberg, Kurt Miller, Ronald de Wit, Peter Mulders, Kim N Chi, Neal D Shore,[...]. N Engl J Med 2012
64

Enzalutamide in metastatic prostate cancer before chemotherapy.
Tomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, Yohann Loriot, Cora N Sternberg, Celestia S Higano, Peter Iversen, Suman Bhattacharya, Joan Carles, Simon Chowdhury,[...]. N Engl J Med 2014
44

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
Charles J Ryan, Matthew R Smith, Karim Fizazi, Fred Saad, Peter F A Mulders, Cora N Sternberg, Kurt Miller, Christopher J Logothetis, Neal D Shore, Eric J Small,[...]. Lancet Oncol 2015
791
42

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Ian F Tannock, Ronald de Wit, William R Berry, Jozsef Horti, Anna Pluzanska, Kim N Chi, Stephane Oudard, Christine Théodore, Nicholas D James, Ingela Turesson,[...]. N Engl J Med 2004
37

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Johann Sebastian de Bono, Stephane Oudard, Mustafa Ozguroglu, Steinbjørn Hansen, Jean-Pascal Machiels, Ivo Kocak, Gwenaëlle Gravis, Istvan Bodrogi, Mary J Mackenzie, Liji Shen,[...]. Lancet 2010
34

Abiraterone in metastatic prostate cancer without previous chemotherapy.
Charles J Ryan, Matthew R Smith, Johann S de Bono, Arturo Molina, Christopher J Logothetis, Paul de Souza, Karim Fizazi, Paul Mainwaring, Josep M Piulats, Siobhan Ng,[...]. N Engl J Med 2013
32

Alpha emitter radium-223 and survival in metastatic prostate cancer.
C Parker, S Nilsson, D Heinrich, S I Helle, J M O'Sullivan, S D Fosså, A Chodacki, P Wiechno, J Logue, M Seke,[...]. N Engl J Med 2013
29

Abiraterone and increased survival in metastatic prostate cancer.
Johann S de Bono, Christopher J Logothetis, Arturo Molina, Karim Fizazi, Scott North, Luis Chu, Kim N Chi, Robert J Jones, Oscar B Goodman, Fred Saad,[...]. N Engl J Med 2011
29

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Karim Fizazi, NamPhuong Tran, Luis Fein, Nobuaki Matsubara, Alfredo Rodriguez-Antolin, Boris Y Alekseev, Mustafa Özgüroğlu, Dingwei Ye, Susan Feyerabend, Andrew Protheroe,[...]. N Engl J Med 2017
26

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
Christopher J Sweeney, Yu-Hui Chen, Michael Carducci, Glenn Liu, David F Jarrard, Mario Eisenberger, Yu-Ning Wong, Noah Hahn, Manish Kohli, Matthew M Cooney,[...]. N Engl J Med 2015
24

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
Ronald de Wit, Johann de Bono, Cora N Sternberg, Karim Fizazi, Bertrand Tombal, Christian Wülfing, Gero Kramer, Jean-Christophe Eymard, Aristotelis Bamias, Joan Carles,[...]. N Engl J Med 2019
213
22

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
Matthew R Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, Boris A Hadaschik, Julie N Graff, David Olmos, Paul N Mainwaring, Ji Youl Lee, Hiroji Uemura,[...]. N Engl J Med 2018
589
21

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Nicholas D James, Johann S de Bono, Melissa R Spears, Noel W Clarke, Malcolm D Mason, David P Dearnaley, Alastair W S Ritchie, Claire L Amos, Clare Gilson, Rob J Jones,[...]. N Engl J Med 2017
852
20

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
Ian D Davis, Andrew J Martin, Martin R Stockler, Stephen Begbie, Kim N Chi, Simon Chowdhury, Xanthi Coskinas, Mark Frydenberg, Wendy E Hague, Lisa G Horvath,[...]. N Engl J Med 2019
479
19

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
Karim Fizazi, Neal Shore, Teuvo L Tammela, Albertas Ulys, Egils Vjaters, Sergey Polyakov, Mindaugas Jievaltas, Murilo Luz, Boris Alekseev, Iris Kuss,[...]. N Engl J Med 2019
348
19

Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.
Tomasz M Beer, Andrew J Armstrong, Dana Rathkopf, Yohann Loriot, Cora N Sternberg, Celestia S Higano, Peter Iversen, Christopher P Evans, Choung-Soo Kim, Go Kimura,[...]. Eur Urol 2017
194
18

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
Maha Hussain, Karim Fizazi, Fred Saad, Per Rathenborg, Neal Shore, Ubirajara Ferreira, Petro Ivashchenko, Eren Demirhan, Katharina Modelska, De Phung,[...]. N Engl J Med 2018
490
18

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
Andrew J Armstrong, Russell Z Szmulewitz, Daniel P Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Arun Azad, Antonio Alcaraz, Boris Alekseev, Taro Iguchi, Neal D Shore,[...]. J Clin Oncol 2019
292
17

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
Karim Fizazi, NamPhuong Tran, Luis Fein, Nobuaki Matsubara, Alfredo Rodriguez-Antolin, Boris Y Alekseev, Mustafa Özgüroğlu, Dingwei Ye, Susan Feyerabend, Andrew Protheroe,[...]. Lancet Oncol 2019
217
17

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Daniel P Petrylak, Catherine M Tangen, Maha H A Hussain, Primo N Lara, Jeffrey A Jones, Mary Ellen Taplin, Patrick A Burch, Donna Berry, Carol Moinpour, Manish Kohli,[...]. N Engl J Med 2004
17

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
Howard I Scher, Michael J Morris, Walter M Stadler, Celestia Higano, Ethan Basch, Karim Fizazi, Emmanuel S Antonarakis, Tomasz M Beer, Michael A Carducci, Kim N Chi,[...]. J Clin Oncol 2016
668
16

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Nicholas D James, Matthew R Sydes, Noel W Clarke, Malcolm D Mason, David P Dearnaley, Melissa R Spears, Alastair W S Ritchie, Christopher C Parker, J Martin Russell, Gerhardt Attard,[...]. Lancet 2016
16

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
Kim N Chi, Neeraj Agarwal, Anders Bjartell, Byung Ha Chung, Andrea J Pereira de Santana Gomes, Robert Given, Álvaro Juárez Soto, Axel S Merseburger, Mustafa Özgüroğlu, Hirotsugu Uemura,[...]. N Engl J Med 2019
445
15

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Emmanuel S Antonarakis, Changxue Lu, Hao Wang, Brandon Luber, Mary Nakazawa, Jeffrey C Roeser, Yan Chen, Tabrez A Mohammad, Yidong Chen, Helen L Fedor,[...]. N Engl J Med 2014
14

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Philip Cornford, Joaquim Bellmunt, Michel Bolla, Erik Briers, Maria De Santis, Tobias Gross, Ann M Henry, Steven Joniau, Thomas B Lam, Malcolm D Mason,[...]. Eur Urol 2017
909
13

Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
Dana E Rathkopf, Matthew R Smith, Johann S de Bono, Christopher J Logothetis, Neal D Shore, Paul de Souza, Karim Fizazi, Peter F A Mulders, Paul Mainwaring, John D Hainsworth,[...]. Eur Urol 2014
180
13

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
13

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
Stéphane Oudard, Karim Fizazi, Lisa Sengeløv, Gedske Daugaard, Fred Saad, Steinbjørn Hansen, Marie Hjälm-Eriksson, Jacek Jassem, Antoine Thiery-Vuillemin, Orazio Caffo,[...]. J Clin Oncol 2017
163
13

Integrative clinical genomics of advanced prostate cancer.
Dan Robinson, Eliezer M Van Allen, Yi-Mi Wu, Nikolaus Schultz, Robert J Lonigro, Juan-Miguel Mosquera, Bruce Montgomery, Mary-Ellen Taplin, Colin C Pritchard, Gerhardt Attard,[...]. Cell 2015
13

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Philip W Kantoff, Celestia S Higano, Neal D Shore, E Roy Berger, Eric J Small, David F Penson, Charles H Redfern, Anna C Ferrari, Robert Dreicer, Robert B Sims,[...]. N Engl J Med 2010
13

Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Chris Tran, Samedy Ouk, Nicola J Clegg, Yu Chen, Philip A Watson, Vivek Arora, John Wongvipat, Peter M Smith-Jones, Dongwon Yoo, Andrew Kwon,[...]. Science 2009
12

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Daniel J Khalaf, Matti Annala, Sinja Taavitsainen, Daygen L Finch, Conrad Oja, Joanna Vergidis, Muhammad Zulfiqar, Katherine Sunderland, Arun A Azad, Christian K Kollmannsberger,[...]. Lancet Oncol 2019
129
12

Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Johann de Bono, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos,[...]. N Engl J Med 2020
536
12

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
Howard I Scher, Susan Halabi, Ian Tannock, Michael Morris, Cora N Sternberg, Michael A Carducci, Mario A Eisenberger, Celestia Higano, Glenn J Bubley, Robert Dreicer,[...]. J Clin Oncol 2008
10

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Perez-Lopez, Daniel Nava Rodrigues, Dan Robinson, Aurelius Omlin, Nina Tunariu,[...]. N Engl J Med 2015
10

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
Dominik R Berthold, Gregory R Pond, Freidele Soban, Ronald de Wit, Mario Eisenberger, Ian F Tannock. J Clin Oncol 2008
781
10

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Gwenaelle Gravis, Karim Fizazi, Florence Joly, Stéphane Oudard, Franck Priou, Benjamin Esterni, Igor Latorzeff, Remy Delva, Ivan Krakowski, Brigitte Laguerre,[...]. Lancet Oncol 2013
406
10

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
9

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Philipp Nuhn, Johann S De Bono, Karim Fizazi, Stephen J Freedland, Maurizio Grilli, Philip W Kantoff, Guru Sonpavde, Cora N Sternberg, Srinivasan Yegnasubramanian, Emmanuel S Antonarakis. Eur Urol 2019
224
9

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Matthew Smith, Chris Parker, Fred Saad, Kurt Miller, Bertrand Tombal, Quan Sing Ng, Martin Boegemann, Vsevolod Matveev, Josep Maria Piulats, Luis Eduardo Zucca,[...]. Lancet Oncol 2019
156
9

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
Michael S Hofman, John Violet, Rodney J Hicks, Justin Ferdinandus, Sue Ping Thang, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Declan G Murphy,[...]. Lancet Oncol 2018
508
9

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.
Emmanuel S Antonarakis, Josep M Piulats, Marine Gross-Goupil, Jeffrey Goh, Kristiina Ojamaa, Christopher J Hoimes, Ulka Vaishampayan, Ranaan Berger, Ahmet Sezer, Tuomo Alanko,[...]. J Clin Oncol 2020
225
9

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Joaquin Mateo, Nuria Porta, Diletta Bianchini, Ursula McGovern, Tony Elliott, Robert Jones, Isabel Syndikus, Christy Ralph, Suneil Jain, Mohini Varughese,[...]. Lancet Oncol 2020
240
9

Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
R J van Soest, M E van Royen, E S de Morrée, J M Moll, W Teubel, E A C Wiemer, R H J Mathijssen, R de Wit, W M van Weerden. Eur J Cancer 2013
156
8

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Christopher C Parker, Nicholas D James, Christopher D Brawley, Noel W Clarke, Alex P Hoyle, Adnan Ali, Alastair W S Ritchie, Gerhardt Attard, Simon Chowdhury, William Cross,[...]. Lancet 2018
530
8

Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.
Andrew J Armstrong, Susan Halabi, Jun Luo, David M Nanus, Paraskevi Giannakakou, Russell Z Szmulewitz, Daniel C Danila, Patrick Healy, Monika Anand, Colin J Rothwell,[...]. J Clin Oncol 2019
167
8

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.
Mario Eisenberger, Anne-Claire Hardy-Bessard, Choung Soo Kim, Lajos Géczi, Daniel Ford, Loïc Mourey, Joan Carles, Phillip Parente, Albert Font, Gabriel Kacso,[...]. J Clin Oncol 2017
136
8

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
Wassim Abida, Akash Patnaik, David Campbell, Jeremy Shapiro, Alan H Bryce, Ray McDermott, Brieuc Sautois, Nicholas J Vogelzang, Richard M Bambury, Eric Voog,[...]. J Clin Oncol 2020
161
8

EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
Philip Cornford, Roderick C N van den Bergh, Erik Briers, Thomas Van den Broeck, Marcus G Cumberbatch, Maria De Santis, Stefano Fanti, Nicola Fossati, Giorgio Gandaglia, Silke Gillessen,[...]. Eur Urol 2021
192
8

Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer.
Philip A Watson, Vivek K Arora, Charles L Sawyers. Nat Rev Cancer 2015
669
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.